SCHEMBL31222190

CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)C(C)C

nearest known ligand 0.56

Predicted protein targets (top 6)

	gene	UniProt	supporting neighbours	confidence
▸	RAMP3	O60896	12/20	0.55

▸	CALCR	P30988	12/20	0.55

▸	NPY2R	P49146	7/20	0.54

▸	NPY4R	P50391	7/20	0.54

▸	NPY5R	Q15761	7/20	0.54

▸	NPY1R	P25929	5/20	0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29522849	0.95	NPY2R (0.55)	RAMP3CALCRNPY2RNPY4RNPY5R
SCHEMBL30726606	0.94	RAMP3 (0.54)	RAMP3CALCRNPY2RNPY4RNPY5R
SCHEMBL31683489	0.93	RAMP3 (0.56)	RAMP3CALCRNPY2RNPY4RNPY5R
SCHEMBL29430214	0.92	MAPK8 (0.61)	RAMP3CALCRNPY2RNPY4RNPY5R
SCHEMBL29430209	0.91	MAPK8 (0.64)	RAMP3CALCRNPY2RNPY4RNPY5R
SCHEMBL30906337	0.91	RAMP3 (0.55)	RAMP3CALCRNPY2RNPY4RNPY5R
SCHEMBL31683295	0.90	NPY2R (0.58)	RAMP3CALCRNPY2RNPY4RNPY5R
SCHEMBL30880885	0.90	RAMP3 (0.55)	RAMP3CALCRNPY2RNPY4RNPY5R
SCHEMBL31000921	0.90	NPY2R (0.63)	RAMP3CALCRNPY2RNPY4RNPY5R
SCHEMBL30906507	0.89	RAMP3 (0.59)	RAMP3CALCRNPY2RNPY4RNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-12152023-B2	Compositions, formulations and methods for treating ocular diseases	EyePoint Pharmaceuticals, Inc. (US)	2024-11-26	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-12152023-B2	Compositions, formulations and methods for treating ocular diseases	TIE1, TEK, KDR	RAMP3 3825/4885CALCR 3044/4885NPY2R 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.